Ying Zeng

Dr. Ying Zeng

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2009 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RCRihong Cong
Rihong Cong
QSQingmin Sun
Qingmin Sun
LYLi Yang
Li Yang
HGHaijuan Gu
Haijuan Gu
YZYing Zeng
Ying Zeng
BWBin Wang
Bin Wang
Background: Vasculogenic mimicry (VM) was increasingly recognized as a form of aggressive melanoma acquiring blood supply. Genistein had attracted much attention as a potential anticancer agent. Therefore, we examined the effect of Genistein on VM in human uveal melanoma cells. Methods: VM structure was detected by periodic acid-Schiff (PAS) staining for uveal melanoma C918 cells cultured on the three-dimensional type I collagen gels after exposed to Genistein. We used reverse transcription polymerase chain reaction (RT-PCR) and Western Blot analysis to examine the effect of Genistein on vascular endothelial cadherin (VE-cadherin) mRNA and protein expression. The nude mice models of human uveal melanoma C918 cells were established to assess the number of VM using immunohistochemical and PAS double-staining. Results: Genistein inhibited the survival of C918 cells in vitro. The ectopic model study showed that VM in tumor tissue sections were significantly reduced by Genistein in vivo. In vitro, the VM structure was found in control, 25 and 50 μM Genistein-treatment groups but not in 100 and 200 μM. RT-PCR and Western Blot showed that 100 and 200 μM concentration of Genistein could significantly decrease VE-cadherin mRNA and protein expression of C918 cells compared with control (P < 0.05). However, the 25 and 50 μM Genistein slightly decreased the VE-cadherin level in vitro (P > 0.05). Conclusion: Genistein inhibits VM formation of uveal melanoma cells in vivo and in vitro. One possible underlying molecular mechanism by which Genistein could inhibit VM formation of uveal melanoma is related to down-regulation of VE-cadherin.

9 December 2022 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
RZRui Zhang
Rui Zhang
YZYing Zeng
Ying Zeng
JDJun-Li Deng
Jun-Li Deng

15 September 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
HZHai-Bo Zhang
Hai-Bo Zhang
YHYang Hu
Yang Hu
JDJun-Li Deng
Jun-Li Deng
GFGuo-Ying Fang
Guo-Ying Fang
YZYing Zeng
Ying Zeng
Doxorubicin is one of the most classical chemotherapeutic drugs for the treatment of cancer. However, resistance to the cytotoxic effects of doxorubicin in tumor cells remains a major obstacle. Aberrant expression of long non-coding RNAs (lncRNAs) has been associated with tumorigenesis and development via regulation of chromatin remodeling, transcription, and post-transcriptional processing. Emerging studies have also revealed that dysregulation of lncRNAs mediates the development of drug resistance through multiple molecules and pathways. In this review, we focus on the role and mechanism of lncRNAs in the progress of doxorubicin resistance in various cancers, which mainly include cellular drug transport, cell cycle disorder, anti-apoptosis, epithelial-mesenchymal transition, cancer stem cells, autophagy, tumor microenvironment, metabolic reprogramming and signaling pathways. This review is aimed to provide potential therapeutic targets for future cancer therapy, especially for the reversal of chemoresistance.

1 January 2023 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
YMYanmei Mao
Yanmei Mao
HZHaibo Zhang
Haibo Zhang
XHXin He
Xin He
JCJing Chen
Jing Chen
LXLanyan Xi
Lanyan Xi
YZYing Zeng
Ying Zeng
Original Article A four-gene signature predicts overall survival of patients with esophageal adenocarcinoma Yanmei Mao, Haibo Zhang, Xin He, Jing Chen, Lanyan Xi, Yanping Chen, Ying Zeng